A B-cell receptor-related gene signature predicts response to ibrutinib treatmeant in mantle cell lymphoma cell lines

Mantle cell lymphoma (MCL) is a B-cell malignancy with a broad range of clinical and biological features. Once all MCL patients were considered to have a poor prognosis. However, it is now fully established that a group of MCL patients may experience an indolent disease without needing treatment for